Tags

  • Sorting

  • Filters

Making Your Vitamin D Testing Dreams Come True

If you work in clinical diagnostics, you can probably confirm that most clinical laboratories have seen a 5 to 6-fold increase in 25-hydroxyvitamin D testing over the past decade, and volume is growing.  Furthermore, the Office of Inspector General (OIG) recently reported Vitamin D as one of the top five laboratory assays reimbursed by Medicare, accounting for 8.7 million laboratory tests and $337 million in reimbursement dollars.

The Science Behind SelexION Differential Mobility Spectrometry Technology

Scientists and analysts across all fields of testing and research are increasingly challenged by complex samples requiring advanced analytical selectivity. And where LC-MS/MS sensitivity alone is not enough to meet the demands of modern day quantitative performance, Differential Ion Mobility Spectrometry (DMS) has proven to be a valuable addition.

Elimination of Interference using the SelexION Differential Mobility System for the Quantitation of Rituximab in a Dual Surrogate Peptide Approach

The quantitation of proteins using the surrogate peptide approach can complicate nominal mass Triple Quadrupole MRM measurements due to co-extracted interference when using non-selective extraction techniques such as pellet digestion. High resolution coupled with accurate mass filtering can mitigate such interference, as reported previously for the determination of rituximab using the TripleTOF 6600 (Protein Quant Approaches). However, an additional level of selectivity can often be achieved on nominal mass systems using the orthogonal gas-phase separation approach offered by the SelexION+® Differential Mobility System technology (DMS). Interfaced between the sampling orifice and ion source, the DMS separates ions based upon differences in their migration rates under alternating low and high field waveform amplitudes (Figure 1). Ion clustering in low fields and declustering in high fields amplifies the distinction in mobility of an ion, resulting in improved resolution from interfering species of differing molecular cross-section.1-4

Happy Birthday to SWATH Acquisition! 5 Years of Innovation

With its introduction at the HUPO World Congress in 2010 in Sydney Australia by Ruedi Aebersold, SWATH® Acquisition instantly intrigued scientists around the world. Here was a new technique with the potential to revolutionize the way proteomics studies were performed! Based on a data independent acquisition strategy using a SCIEX TripleTOF® 5600 system, SWATH was able to consistently identify and quantify at least as many peptides and proteins as other far more mature proteomics strategies on the market, but with quantitative accuracy and reproducibility rivaling gold standard MRM experiments! This solution was made broadly available to researchers with a full launch of SWATH Acquisition in the Analyst® TF 1.6 Software on the TripleTOF 5600+ System at ASMS 2012 in Vancouver (A Mine of Quantitative Proteomic Information.  Prof Dr. Ruedi Aebersold, Head of the Department of Biology, ETH Zurich).

Celebrating customer experience: Insights from SCIEX leaders

Celebrating customer experience: Insights from SCIEX leaders

Customer Experience Day (CX Day) is a special occasion for SCIEX, celebrated every first Tuesday in October. It’s a day dedicated to recognizing the incredible value of our customers and the relentless dedication of our associates who strive to make every interaction meaningful. At SCIEX, our commitment to customer experience is woven into the fabric of everything we do. From providing cutting-edge solutions to offering unwavering support, we aim to build lasting relationships and exceed expectations. Join us as we delve into the insights from our leaders on what customer experience means to SCIEX and how it shapes our journey.

Why traditional MS/MS falls short for ADCs and how electron-activated dissociation (EAD) changes the equation

Why traditional MS/MS falls short for ADCs and how electron-activated dissociation (EAD) changes the equation

Antibody-drug conjugates (ADCs) are among the most promising—and analytically demanding—modalities in biopharma today. By combining large, heterogeneous antibodies with chemically labile payloads and linkers, ADCs introduce a level of structural complexity that challenges conventional analytical workflows. It also poses the challenge that the very features you need to measure are often the easiest to lose during analysis.

Sterile but toxic: Cereulide detection in food matrices

Sterile but toxic: Cereulide detection in food matrices

In a recent webinar, Ming Gao, Ph.D., Senior Research Chemist at Mérieux NutriSciences, explored the growing challenge of cereulide contamination in food products and the analytical strategies needed to detect this heat-stable toxin at trace levels. The session examined how LC-MS/MS can help laboratories overcome the limitations of traditional microbiological screening and meet emerging regulatory requirements.

How SCIEX Now empowers mass spec users to work with more control, clarity and confidence

How SCIEX Now empowers mass spec users to work with more control, clarity and confidence

In this interview, Andy Wilcox, Senior Market Development Manager, Aftermarket and Software, speaks with Susanna Baqué, Senior Director of Global Customer Experience, about how SCIEX Now gives customers one connected digital workspace to manage instruments, reduce time spent searching for information, resolve issues faster and keep their laboratory running more efficiently and with greater confidence.

PFAS explained: What they are, why they matter, and what’s changing

PFAS explained: What they are, why they matter, and what’s changing

PFAS are increasingly at the center of regulatory change, scientific research, and industry discussion worldwide. As analytical capabilities improve and expectations around environmental responsibility continue to evolve, understanding the role PFAS play, and how they are being addressed, has never been more important. This blog provides an overview of what PFAS are, why they matter, and how responses from regulators and industry are changing.

Why electron-activated dissociation (EAD) improves sequence variant analysis in biopharma LC/MS workflows

In biopharmaceutical development, sequence variants (SV) are considered an inherent risk of producing complex proteins in living systems. Sequence variants are unintended changes to the amino acid sequence of a biotherapeutic and can be caused by errors in transcription or translation in the host cell, or cell culture and process conditions. Detailed analysis of SVs is important in process and product development to ensure the drug’s safety and efficacy. Even low‑level sequence variants can have significant implications for product quality, safety, and efficacy, making their accurate detection and characterization a critical requirement across development, process optimization, and regulatory submission.  

No Results Found

The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.

No Results Found

The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.

Pin It on Pinterest